Katsiaryna Vasilyeva
Family · Berwyn, PANPI 1659896025
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,939 of the $16,248 with a category attached, or 73.5%. AbbVie accounts for 85.3% of it on its own, with 22 other manufacturers making up the rest. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $85.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- SK Life Science, Inc.$345
- TG Therapeutics, Inc.$275
- Lundbeck LLC$251
- UCB, Inc.$250
- Amgen$205
- plus $1K from 17 others
What the payments were for
- Consulting fees$1381%
- Speaking & faculty fees$11,93973%
- Food & beverage$4,17126%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 125 | $13,856 |
| SK Life Science, Inc. | 6 | $345 |
| TG Therapeutics, Inc. | 2 | $275 |
| Lundbeck LLC | 6 | $251 |
| UCB, Inc. | 10 | $250 |
| Amgen | 3 | $205 |
| Impel Pharmaceuticals Inc. | 7 | $179 |
| Pfizer | 8 | $161 |
| Lilly USA, LLC | 2 | $138 |
| Novo Nordisk | 1 | $120 |
| Teva Pharmaceuticals USA, Inc. | 4 | $78 |
| Biohaven Pharmaceuticals, Inc. | 2 | $59 |
| Axsome Therapeutics, Inc. | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Neurelis, Inc. | 2 | $40 |
| Saluda Medical Americas, Inc. | 1 | $33 |
| Upsher-smith Laboratories LLC | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Averitas Pharma Inc. | 1 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $23 |
| Impel Pharmaceuticals LLC | 1 | $22 |
| Tonix Medicines, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,248 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 63 | $93,075 |
| Nurtec OdtRimegepant Sulfate | 68 | $85,758 |
| QuliptaAtogepant | 26 | $36,242 |
| Aimovig AutoinjectorErenumab-Aooe | 37 | $35,685 |
| Emgality PenGalcanezumab-Gnlm | 23 | $16,880 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 15 | $13,894 |
| SavellaMilnacipran Hcl | 16 | $8,696 |
| Gabapentin | 41 | $1,783 |
| RizatriptanRizatriptan Benzoate | 55 | $1,282 |
| Sumatriptan Succinate | 45 | $717 |
| Memantine Hcl | 15 | $604 |
| Topiramate | 36 | $441 |
| Verapamil Hcl | 23 | $341 |
| Cyclobenzaprine Hcl | 20 | $341 |
| Tizanidine Hcl | 21 | $259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Savella | $13,856 | $138,014105 claims |
| PfizerNurtec Odt | $161 | $85,75868 claims |
| Upsher-smith Laboratories LLCTopiramate | $28 | $44136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Berwyn
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.